Novartis Pharmaceuticals
The objective of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients newly started on erenumab over 12 weeks
Migraine
erenumab
This is a longitudinal prospective descriptive primary data collection using a 20 min online survey. Patients will be selected by investigators (general neurologists, headache/migraine specialists) in primary care clinics and hospitals. After fulfilling the inclusion criteria, the patient will be asked to sign an online informed consent. A 5 min screener will follow after which the patient will be directed through a link to the full survey. The duration of data collection will be for 6 months since the start of survey rolling in each site across centers in the Gulf Region.
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 200 participants |
Official Title : | Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study |
Actual Study Start Date : | 2024-06-05 |
Estimated Primary Completion Date : | 2025-03-30 |
Estimated Study Completion Date : | 2025-03-30 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 100 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Novartis Investigative Site
Abu Dhabi, United Arab Emirates,
RECRUITING
Novartis Investigative Site
Ras Al Khaimah, United Arab Emirates,